Lumoxiti FDA Approval History
FDA Approved: Yes (First approved September 13, 2018)
Brand name: Lumoxiti
Generic name: moxetumomab pasudotox-tdfk
Dosage form: Injection
Treatment for: Hairy Cell Leukemia
Lumoxiti (moxetumomab pasudotox-tdfk) is an anti-CD22 recombinant immunotoxin for the treatment of adult patients with hairy cell leukemia.
Development timeline for Lumoxiti
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.